Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Non-small cell lung cancer (NSCLC) patients often develop resistance to standard taxane-platin chemotherapy, leading to relapse.
• A significant challenge in NSCLC treatment is overcoming acquired chemoresistance.
• Identifying novel therapeutic targets is crucial for improving treatment efficacy.

Purpose of the Study:

• To investigate the role of JumonjiC demethylases in taxane-platin chemoresistance in NSCLC.
• To evaluate the efficacy of JumonjiC inhibitors as a therapeutic strategy against chemoresistant NSCLC.
• To identify biomarkers associated with chemoresistance and therapeutic response.

Main Methods:

• Establishment of preclinical taxane-platin-chemoresistance models in NSCLC.
• Identification of a 35-gene resistance signature, including KDM3B.
• In vitro and in vivo assessment of JumonjiC inhibitors (JIB-04, GSK-J4) in chemoresistant cells and patient samples.
• Analysis of histone methylation and transcriptional programs.

Main Results:

• A 35-gene resistance signature, including KDM3B upregulation, was identified and correlated with poor survival in NSCLC patients.
• Multi-drug-resistant NSCLC cells exhibited increased JumonjiC demethylase expression, altered histone methylation, and hypersensitivity to JumonjiC inhibitors.
• JumonjiC inhibitors reversed deregulated transcriptional programs, prevented drug-tolerant colony formation, and synergized with standard chemotherapy.
• Progressive chemoresistance correlated with increased sensitivity to JIB-04 and GSK-J4.

Conclusions:

• JumonjiC demethylases are key players in taxane-platin chemoresistance in NSCLC.
• JumonjiC inhibitors demonstrate significant potential as a novel therapeutic approach for chemoresistant NSCLC.
• Combination therapy with standard chemotherapy and JumonjiC inhibitors may overcome treatment resistance and improve patient outcomes.